Seelos therapeutics announces acquisition of an exclusive license of ix biopharma's proprietary wafer-based delivery platform for sublingual ketamine

New york, nov. 24, 2021 /prnewswire/ -- seelos therapeutics, inc. (nasdaq: seel), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has entered into an exclusive license agreement (license agreement), whereby it acquired a worldwide license (excluding china, taiwan, macau and hong kong) from ix biopharma ltd (ix biopharma) for wafermine™, a sublingual racemic ketamine wafer, and a worldwide license for other sublingual ketamine wafers, delivered using a proprietary fast-dissolving wafer-based drug delivery platform technology known as waferix™. seelos plans to evaluate sublingual ketamine, now named sls-003, in pain indications such as chronic neuropathic pain and complex regional pain syndrome (crps) and in additional psychiatric disorders, including post-traumatic stress disorder (ptsd).
SEEL Ratings Summary
SEEL Quant Ranking